Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sotatercept on Exercise Performance in Pulmonary Arterial Hypertension
NCT06409026Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Mayo Clinic. Primary endpoint: Pulmonary arterial mean pressure/Cardiac Output at peak exercise at 24 weeks. Started Jul 2024; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06409026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409026.